PD-1(programmed cell death-1，程序性死亡受体1)与其配体PD-L1 (programmed cell death-ligand 1，程序性死亡配体1)属于CD28/B7家族，是一对共刺激分子，具有负性调控作用。PD-1通过与其配体PD-L1结合调节肿瘤的微环境，使肿瘤细胞免于机体免疫系统的监视和清除。目前已有较多研究显示PD-1/PD-L1在非小细胞肺癌组织中的表达水平与患者的临床病理因素及预后存在显著的相关性。在非小细胞肺癌的治疗领域，以PD-1/PD-L1为代表的免疫治疗成为继手术治疗、化疗、放疗、分子靶向治疗之后的新焦点。PD-1/PD-L1抑制剂在一系列非小细胞肺癌临床试验中也显示出了巨大的临床潜力。本文就PD-1/PD-L1的生物学结构及其在非小细胞肺癌中的作用机制、研究进展及展望作一综述。
Research progress and prospect of PD-1/PD-L1 in non-small cell lung cancer
PD-1 (programmed cell death, PD-1) and its ligand PD-L1 (programmed cell death-ligand 1, PD-L1) belonged to the immunoglobulin superfamily of CD28/B7, is a pair of co-stimulatory molecule which has negative regulation effect. Combined with ligands, PD-1 could modulate the tumor microenvironment, leading the tumor cells scape from host Immune surveillance and elimination. Recently, many studies showed that PD-1/PD-L1 expression in non-small cell lung cancer (NSCLC) was substantially related to clinicopathologic and prognostic factors of patients. After surgery, chemotherapy, radiotherapy and molecular targeting therapy, immune therapy targeting PD-1/PD-L1 has become the new focus of NSCLC therapy in recent years. It has shown durable responses in clinical trials with large NSCLC expansion cohorts. This review summarizes the biological structure and the critical role of PD 1/PD-L1 in NSCLC as well as its current research status and future direction.